- Newsletter
- September 2025
- 3 Pages
Global
From €116EUR$131USD£101GBP
- Report
- August 2025
Global
From €754EUR$850USD£654GBP
- Report
- January 2025
- 132 Pages
Global
From €843EUR$950USD£731GBP
- Report
- September 2024
- 220 Pages
China
From €3548EUR$4,000USD£3,077GBP
- Report
- September 2024
- 65 Pages
China
From €1596EUR$1,800USD£1,385GBP
- Report
- September 2024
- 109 Pages
China
From €1596EUR$1,800USD£1,385GBP
- Report
- August 2024
- 214 Pages
China
From €3548EUR$4,000USD£3,077GBP
- Report
- August 2024
- 92 Pages
China
From €1596EUR$1,800USD£1,385GBP
- Report
- March 2024
- 132 Pages
Global
From €843EUR$950USD£731GBP
- Report
- March 2024
- 132 Pages
Global
From €843EUR$950USD£731GBP
- Report
- March 2024
- 132 Pages
Global
From €843EUR$950USD£731GBP
- Report
- March 2024
- 132 Pages
Global
From €843EUR$950USD£731GBP
- Report
- June 2023
- 132 Pages
Global
From €843EUR$950USD£731GBP
- Report
- September 2022
Philippines
From €1641EUR$1,850USD£1,423GBP
- Report
- August 2022
Latin America
From €12861EUR$14,500USD£11,155GBP
- Report
- August 2022
Asia Pacific
From €12861EUR$14,500USD£11,155GBP

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump.
The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more